Genen­tech inks its lat­est dis­cov­ery deal — this time turn­ing to RNA up­start Sky­hawk

Roche’s Genen­tech has just com­plet­ed the lat­est in a string of dis­cov­ery deals with a line­up of much, much small­er com­pa­nies look­ing to do new things in drug de­vel­op­ment.

Right on the heels of the news of So­sei’s coup bring­ing Genen­tech on board as a part­ner for its GPCR plat­form, the pro­lif­ic deal­mak­ers at Sky­hawk — run by Bill Haney — have just added the sto­ried biotech sub­sidiary as its lat­est part­ner in the world of drug­ging RNA.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER